Matthew P. Hanley

Genome-wide DNA methylation profiling reveals cancer-associated changes within early colonic neoplasia

Matthew P. Hanley, Maria A. Hahn, A X Li et al. · Oncogene · 2017 · 105 citations · Full text

Life Sciences, Genetics, Oncology +16

Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <i>EGFR</i> -Mutant and <i>RET</i> Fusion-Positive Lung Cancers

Julia Rotow, Jyoti D. Patel, Matthew P. Hanley et al. · Clinical Cancer Research · 2023 · 40 citations · Full text

Medicine, Oncology, Pharmacology +17

Dietary Methyl Donor Depletion Suppresses Intestinal Adenoma Development

Matthew P. Hanley, Krishna Kadaveru, Christine Perret et al. · Cancer Prevention Research · 2016 · 25 citations · Full text

Medicine, Nutritional Sciences, Oncology +15

A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors.

James M. Pauff, Kyriakos P. Papadopoulos, Filip Jankú et al. · Journal of Clinical Oncology · 2021 · 25 citations

Medicine, Oncology, Pharmacology +13

FP14.07 Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions

Julia Rotow, Jyoti D. Patel, Matthew P. Hanley et al. · Journal of Thoracic Oncology · 2021 · 25 citations · Full text

Medicine, Oncology, Pharmacology +16